DOCSLIB.ORG

Acquired Infections

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Acquired Infections ECDC TECHNICAL DOCUMENT Surveillance of healthcare-associated infections and prevention indicators in European intensive care units HAI-Net ICU protocol, version 2.2 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. Contributing authors Anne Savey, Alain Lepape (France), Mercedes Palomar (Spain), Antonella Agodi (Italy), Michael Hiesmayr (Austria), Anna-Pelagia Magiorakos, Pete Kinross, Tommi Kärki, Diamantis Plachouras, Carl Suetens (ECDC) In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. Acknowledgements: ECDC would like to thank the HAI-Net ICU operational contact points and Member States experts for providing input during meetings (October 2013, February 2014, February 2015), as well as the European Society of Intensive Care Medicine (Infection Section) for reviewing and commenting on the structure and process indicators of the protocol (Members: Jean-Francois Timsit (France, Infection Section Chair), Christian Brun- Buisson (France), Massimo Antonelli (Italy), Despoina Koulenti (Greece/Australia), José Artur Paiva (Portugal), Stijn Blot (Belgium), Jan De Waele (Belgium, Chair from January 2015). The current HAI-Net ICU protocol v2.2 is the final version of the new HAI-Net ICU protocol, slightly adapted after the pilot version 2.0 in the fall of 2015. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections and prevention indicators in intensive care units – HAI-Net ICU protocol, version 2.2. Stockholm: ECDC, 2017. Stockholm, 2017 © European Centre for Disease Prevention and Control, 2017 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 2.1 Table of contents Abbreviations ................................................................................................................................................ v Introduction and objectives.............................................................................................................................1 1 HAI-Net ICU protocol v2.2: summary of main changes ...................................................................................3 2 Patient-based (standard option) versus unit-based (light option) surveillance of ICU-acquired infections ............. 3 3 Case definitions of ICU-acquired infections ....................................................................................................5 3.1 Definition of key terms ..........................................................................................................................5 3.1.1 ICU-acquired ..................................................................................................................................5 3.1.2 Second infection episode .................................................................................................................5 3.1.3 Device-associated HAI .....................................................................................................................5 3.2 Bloodstream infection ............................................................................................................................6 3.2.1 Case definition ................................................................................................................................6 3.2.2 Origin of BSI ...................................................................................................................................6 3.3 Pneumonia (PN 1–PN 5) ........................................................................................................................7 X-ray .......................................................................................................................................................7 Symptoms ..............................................................................................................................................7 Microbiology ...........................................................................................................................................7 3.4 Urinary tract infection ............................................................................................................................8 3.4.1 UTI-A: microbiologically confirmed symptomatic urinary tract infection (UTI) ....................................... 8 3.4.2 UTI-B: not microbiologically confirmed symptomatic UTI .................................................................... 8 3.5 Catheter-related infection (CRI) ..............................................................................................................8 3.5.1 CRI1-CVC: local CVC-related infection (no positive blood culture) ........................................................ 8 3.5.2 CRI2-CVC: general CVC-related infection (no positive blood culture) .................................................... 8 3.5.3 CRI3-CVC: microbiologically confirmed CVC-related bloodstream infection ............................................ 8 3.6 Other HAI types ....................................................................................................................................9 3.7 Other definitions ................................................................................................................................. 10 3.6.1 Central vascular catheter ............................................................................................................... 10 3.6.2 Type of hospital ............................................................................................................................ 10 4 Data collection .......................................................................................................................................... 11 4.1 Eligibility criteria for intensive care units ................................................................................................ 11 4.2 Inclusion of patients ............................................................................................................................ 11 4.3 Infections under surveillance ................................................................................................................ 12 4.4 Methods and data sources ................................................................................................................... 12 4.4.1 Structure and process indicators ..................................................................................................... 12 4.4.2. Patient and HAI data .................................................................................................................... 13 4.5 Data processing .................................................................................................................................. 13 4.6 Levels of data requirement .................................................................................................................. 13 5 Hospital/unit data (standard and light options) ............................................................................................ 14 5.1 Hospital and unit characteristics – Form HU ........................................................................................... 14 5.2 ICU denominator data – Form HU ......................................................................................................... 14 5.3 Structure and process indicators – Form HU .......................................................................................... 15 6. Patient-based data (standard option) – Form PT ......................................................................................... 18 6.1. ICU admission and discharge data (second level) .................................................................................. 18 6.2 Exposure data (third level) ................................................................................................................... 19 6.3 Antimicrobial use data (third level) ....................................................................................................... 19 iii HAI-Net ICU protocol, version 2.1 TECHNICAL DOCUMENT 7. HAI data (standard and light options) – Form INF ....................................................................................... 22 7.1. Infection data (third level) .................................................................................................................. 22 7.2 Microorganism and antimicrobial resistance data (fourth level) ................................................................ 23 8 Outcome indicators of ICU-acquired infections ............................................................................................. 27 9 Confidentiality ........................................................................................................................................... 27 9.1 Patient confidentiality .......................................................................................................................... 27 9.2 Hospital and unit confidentiality ...........................................................................................................
Load more

Recommended publications
  • WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/11 (2006.01) A61K 38/08 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2015/031213 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 15 May 2015 (15.05.2015) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/000,43 1 19 May 2014 (19.05.2014) US kind of regional protection available): ARIPO (BW, GH, 62/129,746 6 March 2015 (06.03.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors; and TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicants : GELLER, Bruce, L.
    [Show full text]
  • Conference on Predicting Cell Metabolism and Phenotypes
    Conference on Predicting Cell Metabolism and Phenotypes Barry Bochner, Biolog, Inc., [email protected] Brief History of Metabolic Phenotypic Analysis In the beginning … The cell was a black box Early Beginnings of Metabolic Description of Cells Bergey’s Manual 1st Edition, 1923 L. E. den Dooren de Jong Survey of C-Source and N-Source Utilization, 1926 B. coli M. phlei Analogy #1 Metabolic Circuitry Resembles Electronic Circuits View of Cells circa 1960 Regulatory Complexity Added to Circuitry, circa 1970 feedback inhibition, synthetic pathways A B C D E F G feedforward activation, catabolic pathways Feedback and feedforward open up the possibility of oscillations Metabolic Oscillations Metabolic Oscillations A single gene mutation causes cell growth to oscillate ! Histidine secretion Histidine limitation Metabolism Resembles Electronic Circuit Diagrams Electrical Components Biological Components Dehydrogenases Polymerases Isomerases Kinases Glycosidases Hydrolases Phosphatases Epimerases Phosphorylases Transferases Peptidases Proteases Oxidoreductases Lyases Aldolases Ligases Hydroxylases Cyclases Higher Order Understanding of Electronic Circuits Amplifier Receiver Rectifier Oscillator Integrator Comparator Counter Filter Higher Order Understanding of Cells: Physiology • Growth is a property common to all cells • Cell growth is primarily polymer synthesis: DNA, RNA, protein, membranes, wall, storage polymers • The polymers are made by assembling subunits: deoxynucleotides, ribonucleotides, amino acids, etc. • The subunits are made from
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith Et Al
    USOO9662400B2 (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith et al. (45) Date of Patent: *May 30, 2017 (54) METHODS FOR PRODUCING A (2013.01); C08B 37/003 (2013.01); C08L 5/08 BODEGRADABLE CHITOSAN (2013.01); A6 IK 38/00 (2013.01); A61 L COMPOSITION AND USES THEREOF 2300/404 (2013.01) (58) Field of Classification Search (71) Applicant: University of Memphis Research CPC ...... A61K 47/36; A61K 31/00; A61K 9/7007; Foundation, Memphis, TN (US) A61K 9/0024; A61 L 15/28: A61L 27/20; A61L 27/58: A61L 31/042; C08B 37/003 (72) Inventors: James Keaton Smith, Memphis, TN USPC ................................ 514/23, 40, 777; 536/20 (US); Ashley C. Parker, Memphis, TN See application file for complete search history. (US); Jessica A. Jennings, Memphis, (56) References Cited TN (US); Benjamin T. Reves, Memphis, TN (US); Warren O. U.S. PATENT DOCUMENTS Haggard, Bartlett, TN (US) 4,895,724. A * 1/1990 Cardinal .............. A61K9/0024 424,278.1 (73) Assignee: The University of Memphis Research 5,541,233 A 7/1996 Roenigk Foundation, Memphis, TN (US) 5,958,443 A 9/1999 Viegas et al. 6,699,287 B2 3/2004 Son et al. (*) Notice: Subject to any disclaimer, the term of this 6,989,157 B2 1/2006 Gillis et al. patent is extended or adjusted under 35 7,371.403 B2 5/2008 McCarthy et al. 2003, OO15825 A1 1/2003 Sugie et al. U.S.C. 154(b) by 0 days. 2003/0206958 A1 11/2003 Cattaneo et al.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Food Sample Preparation for the Determination of Sulfonamides by High-Performance Liquid Chromatography: State-Of-The-Art
    separations Review Food Sample Preparation for the Determination of Sulfonamides by High-Performance Liquid Chromatography: State-of-the-Art Dimitrios Bitas 1, Abuzar Kabir 2 ID , Marcello Locatelli 3 ID and Victoria Samanidou 1,* ID 1 Laboratory of Analytical Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; [email protected] 2 International Forensic Research Institute, Department of Chemistry and Biochemistry, Florida International University, 11200 SW 8th St, Miami, FL 33199, USA; akabir@fiu.edu 3 Department of Pharmacy, University “G. d’Annunzio” of Chieti-Pescara, 66100 Chieti, Italy; [email protected] * Correspondence: [email protected]; Tel.: +30-231-099-7698 Received: 30 April 2018; Accepted: 28 May 2018; Published: 4 June 2018 Abstract: Antibiotics are a common practice in veterinary medicine, mainly for therapeutic purposes. Sectors of application include livestock farming, aquacultures, and bee-keeping, where bacterial infections are frequent and can be economically damaging. However, antibiotics are usually administered in sub-therapeutic doses as prophylactic and growth promoting agents. Due to their excessive use, antibiotic residues can be present in foods of animal origin, which include meat, fish, milk, eggs, and honey, posing health risks to consumers. For this reason, authorities have set maximum residue limits (MRLs) of certain antibiotics in food matrices, while analytical methods for their determination have been developed. This work focuses on antibiotic extraction and determination, part of which was presented at the “1st Conference in Chemistry for Graduate, Postgraduate Students and PhD Candidates at the Aristotle University of Thessaloniki”. Taking a step further, this paper is a review of the most recent sample preparation protocols applied for the extraction of sulfonamide antibiotics from food samples and their determination with high-performance liquid chromatography (HPLC), covering a five-year period.
    [Show full text]
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Drug
    Quantitative Safety & Epidemiology NVA237 / Glycopyrronium bromide Non-interventional Final Study Report NVA237A2401T Multinational, multi-database drug utilization study of inhaled NVA237 in Europe Author Document Status Final Date of final version 28 April 2016 of the study report EU PAS register ENCEPP/SDPP/4845 number Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis NIS Report Template Version 2.0 August-13-2014 Novartis Confidential Page 2 Non-interventional study report NVA237A/Seebri® Breezhaler®/CNVA237A2401T PASS information Title Multinational, multi-database drug utilization study of inhaled NVA237 in Europe –Final Study Report Version identifier of the Version 1.0 final study report Date of last version of 28 April 2016 the final study report EU PAS register number ENCEPP/SDPP/4845 Active substance Glycopyrronium bromide (R03BB06) Medicinal product Seebri®Breezhaler® / Tovanor®Breezhaler® / Enurev®Breezhaler® Product reference NVA237 Procedure number SeebriBreezhaler: EMEA/H/C/0002430 TovanorBreezhaler: EMEA/H/C/0002690 EnurevBreezhaler: EMEA/H/C0002691 Marketing authorization Novartis Europharm Ltd holder Frimley Business Park Camberley GU16 7SR United Kingdom Joint PASS No Research question and In the context of the NVA237 marketing authorization objectives application, the Committee for Medicinal Products for Human Use (CHMP) recommended conditions for marketing authorization and product information and suggested to conduct a post-authorization
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
    www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 “Drug Design strategy and chemical process maximization in the light of Molecular Hybridization Concept.” Subhasis Basu, Ph D Registration No: VB 1198 of 2018-2019. Department Of Chemistry, Visva-Bharati University A Draft Thesis is submitted for the partial fulfilment of PhD in Chemistry Thesis/Degree proceeding. DECLARATION I Certify that a. The Work contained in this thesis is original and has been done by me under the guidance of my supervisor. b. The work has not been submitted to any other Institute for any degree or diploma. c. I have followed the guidelines provided by the Institute in preparing the thesis. d. I have conformed to the norms and guidelines given in the Ethical Code of Conduct of the Institute. e. Whenever I have used materials (data, theoretical analysis, figures and text) from other sources, I have given due credit to them by citing them in the text of the thesis and giving their details in the references. Further, I have taken permission from the copyright owners of the sources, whenever necessary. IJCRT2012039 International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org 284 www.ijcrt.org © 2020 IJCRT | Volume 8, Issue 12 December 2020 | ISSN: 2320-2882 f. Whenever I have quoted written materials from other sources I have put them under quotation marks and given due credit to the sources by citing them and giving required details in the references. (Subhasis Basu) ACKNOWLEDGEMENT This preface is to extend an appreciation to all those individuals who with their generous co- operation guided us in every aspect to make this design and drawing successful.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Evaluating Risks from Antibacterial Medication Therapy
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations Summer 2010 Evaluating Risks from Antibacterial Medication Therapy Sharon B. Meropol University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Therapeutics Commons Recommended Citation Meropol, Sharon B., "Evaluating Risks from Antibacterial Medication Therapy" (2010). Publicly Accessible Penn Dissertations. 424. https://repository.upenn.edu/edissertations/424 A version of Chapter 3 has been published: Meropol SB, Chen Z, Metlay JP. Reduced antibiotic use for acute respiratory infections in adults and children. Br J Gen Prac. Oct. 2009; 59(567)3321-328.DOI:10.3399/ bjgp09X472610. E321-328 PMID: 19843412 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/424 For more information, please contact [email protected]. Evaluating Risks from Antibacterial Medication Therapy Abstract ABSTRACT EVALUATING RISKS FROM ANTIBACTERIAL MEDICATION THERAPY USING AN OBSERVATIONAL PRIMARY CARE DATABASE Sharon B. Meropol Joshua P. Metlay Virtually everyone in the U.S. is exposed to antibacterial drugs at some point in their lives. It is important to understand the benefits and risks elatedr to these medications with nearly universal public exposure. Most information on antibacterial drug-associated adverse events comes from spontaneous reports. Without an unexposed control group, it is impossible to know the real risks for treated vs. untreated patients. We used an electronic medical record database to select a cohort of office visits for non-bacterial acuteespir r atory tract infections (excluding patients with pneumonia, sinusitis, or acute exacerbations of chronic bronchitis), and compared outcomes of antibacterial drug-exposed vs.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]